

Message

From: Gillespie, Taylor [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=99194195C10A4515A7E4A0328B69BCD3-GILLESPIE,]
Sent: 8/17/2022 11:10:42 AM
To: Koerber, Mike [Koerber.Mike@epa.gov]
Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

I don't think he is under any commitment either but it would be good to confirm which meetings you and Tomas are planning to participate in today. I think there is definitely some confusion swirling in the regions and they want to know for planning because they are working on scripts. Also, if you aren't joining in Laredo then we really need to do some practice with Jeff, Kim, and David in Laredo.

For the Utah meeting that the State is leading tonight, Madeline is kicking it off with three slides and then Kerry Hicks has two slides. They are trying to be mindful that the call doesn't morph into the actual community meeting. There isn't a lot of interest in the community so they actually expect it'll mainly be lobbyists/company advocates on the call.

Taylor Gillespie (she/her)
Strategic Communications Advisor
Environmental Protection Agency
872-276-3635 (mobile)
Twitter: @EPAPressOffice

From: Koerber, Mike <Koerber.Mike@epa.gov>
Sent: Tuesday, August 16, 2022 12:31 PM
To: Gillespie, Taylor <Gillespie.Taylor@epa.gov>
Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Who from HQ is attending?

Also, I talked with Tomas today about the PR meeting. He's able to attend but is under the impression that he's made no formal commitment to attend. He's going to raise it on tomorrow's check-in to make he knows his role.

Mike

From: Gillespie, Taylor <Gillespie.Taylor@epa.gov>
Sent: Tuesday, August 16, 2022 12:25 PM
To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>; Beal, Madeline <Beal.Madeline@epa.gov>
Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>
Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Hi Aftin – I wanted to follow up and let you know that Madeline and I had a call scheduled with the State of Utah and our Region 8 office to discuss the planning for the September 8th community meeting in Sandy, Utah. We decided to move EPA's meeting from September 8 to October 20. We made this decision because EPA representatives from HQ

and the regional office are now planning to join and give a couple minutes of remarks on the State led meeting being held tomorrow evening.

Thanks,

Taylor Gillespie (she/her)
Strategic Communications Advisor
Environmental Protection Agency
872-276-3635 (mobile)
Twitter: @EPAPressOffice

From: Ross, Aftin <Aftin.Ross@fda.hhs.gov>
Sent: Tuesday, August 16, 2022 9:08 AM
To: Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>
Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>
Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Thank you for the additional information.

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-796-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>



From: Gillespie, Taylor <Gillespie.Taylor@epa.gov>
Sent: Monday, August 15, 2022 12:04 PM
To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>; Beal, Madeline <Beal.Madeline@epa.gov>
Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita

<Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Utah DAQ gave some initial monitoring results to the their Air Quality Policy Advisory Board which was open to the public but only a few board members attended. There have been other community meetings but none specific to EtO.

The State meeting is being recorded. It doesn't appear that anyone from Region 8 is currently planning to listen in the evening but they were planning to watch the recording the next morning.

Taylor Gillespie (she/her)
Strategic Communications Advisor
Environmental Protection Agency
872-276-3635 (mobile)
Twitter: @EPAPressOffice

From: Ross, Aftin <Aftin.Ross@fda.hhs.gov>

Sent: Monday, August 15, 2022 11:25 AM

To: Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Also, one more question. Will the EPA region be attending the meeting and if so, do you know who their representative will be?

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-798-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>



From: Ross, Aftin

Sent: Monday, August 15, 2022 11:07 AM

To: 'Gillespie, Taylor' <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Thank you very much Taylor for obtaining this additional context for the region. This is very helpful. Just one clarifying question, has the state had previous engagement with the community on EtO previously?

Best,

Aftin

Aftin Ross, Ph.D.

Senior Special Advisor for Emerging Initiatives

Office of Strategic Partnerships and Technology Innovation (OST)

Center for Devices and Radiological Health

U.S. Food and Drug Administration

WO 66, Room 5558

10903 New Hampshire Ave, Silver Spring, MD 20993

Office: 301-796-5679; Cell: **FDA Ex. 6 PP**

aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>



From: Gillespie, Taylor <Gillespie.Taylor@epa.gov>

Sent: Monday, August 15, 2022 10:50 AM

To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>; Beal, Madeline <Beal.Madeline@epa.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Aftin – Here is a summary of the meeting from our regional office.

The state has a Community Scale Air Toxics Ambient Monitoring grant provided by the EPA to monitor EtO surrounding Sterigenics, in Salt Lake City (close to the airport, not a lot of residences, a lot of businesses and warehouses, not on our list of high risk facilities), BD Medical in Sandy, and background sites around the city. As a follow up to our National Public Webinar held on Aug 10th, UDEQ plans to share some basics reiterated from our national webinar and then share what UDEQ is doing to better understand the situation and address concerns of the community. The state will share some of their preliminary monitoring results that are consistent with modelling from EPA. They will also share the plans of BD Medical to upgrade the facility and reduce emissions almost entirely (90-95%) and direct the audience to a BD Medical website for more info. The meeting will conclude with some Q&As and have DHHS and Salt Lake City Health officials on the call to help support. The meeting is only scheduled for an hour and UDEQ will share information about our Sept 8 meeting.

Taylor Gillespie (she/her)
Strategic Communications Advisor
Environmental Protection Agency
872-276-3635 (mobile)
Twitter: @EPAPressOffice

From: Ross, Aftin <Aftin.Ross@fda.hhs.gov>
Sent: Monday, August 15, 2022 9:56 AM
To: Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>
Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>
Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Good morning Taylor and thanks for additional information. We are just trying to get a better understanding of what this meeting is and the context. Our understanding, was that the EPA region was not going to be participating in the meeting and that there wouldn't be a meeting with the community until October. If EPA wasn't participating, we were asking whether the region would reconsider participating to help ensure the community's understanding of the issues EPA shared during its national webinar.

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-796-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>

From: Gillespie, Taylor <Gillespie.Taylor@epa.gov>

Sent: Monday, August 15, 2022 9:47 AM

To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>; Beal, Madeline <Beal.Madeline@epa.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Aftin – Madeline and I are leading a virtual community meeting with EPA regional staff in regards to the commercial sterilizer in Sandy, Utah EtO on the evening of September 8. We are meeting with the State later this week to consider having them join us for that community meeting. There have been ongoing community meetings in Sandy, Utah in regards to EtO for a while and my understanding is that the State is holding this meeting to discuss the air monitoring that has been ongoing. It is my understanding that Region 8 staff will be listening to the meeting that evening and that this community is well informed about the risks from the commercial sterilizer in their community.

Mike – Can you confirm that the data we recently released is actually lower for the facility in Sandy, Utah than what we shared previously?

Since the EPA Region 8 office are two hours behind, it may be another hour or so until we hear from them to confirm exactly who is attending from the regional office and if they have any other details about this meeting.

What exactly do you want the Region 8 office to reconsider?

Taylor Gillespie (she/her)
Strategic Communications Advisor
Environmental Protection Agency
872-276-3635 (mobile)
Twitter: @EPAPressOffice

From: Ross, Aftin <Aftin.Ross@fda.hhs.gov>

Sent: Monday, August 15, 2022 9:36 AM

To: Beal, Madeline <Beal.Madeline@epa.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: RE: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Thanks for the additional context Madeline and appreciate the outreach recognizing the challenges with work travel. Due to the criticality of this facility to the device supply chain (see attached 1 pager for more context), is it possible to ask the region to reconsider? Perhaps FDA speaking with them for additional context would be of benefit.

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-796-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>



From: Beal, Madeline <Beal.Madeline@epa.gov>

Sent: Monday, August 15, 2022 9:28 AM

To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>

Cc: Koerber, Mike <Koerber.Mike@epa.gov>; Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: Re: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

I'm on work travel this week so may be slightly slower to respond.

The meeting you mention is not EPAs meeting. We are hosting our community meeting later in September (Taylor can tell you the exact date.)

The meeting referenced below is hosted by the state. They didn't want to wait for our scheduled meeting and the region made the decision not to participate at this time and to focus on planning for the meeting in September.

-Madeline

Sent from my iPhone

On Aug 15, 2022, at 8:17 AM, Ross, Aftin <Aftin.Ross@fda.hhs.gov> wrote:

Good morning. I hope your week is off to a great start. I just wanted to bring the email below, back to the top of the EPA team's inboxes as we begin the week. Any insights you can provide will be greatly appreciated.

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-796-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:

<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>



From: Ross, Aftin <Aftin.Ross@fda.hhs.gov>

Sent: Friday, August 12, 2022 6:21 PM

To: Koerber, Mike <Koerber.Mike@epa.gov>; Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>

Cc: Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: Re: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

Thanks Mike.

Best,

Aftin

Get [Outlook for iOS](#)

From: Koerber, Mike <Koerber.Mike@epa.gov>

Sent: Friday, August 12, 2022 5:58:13 PM

To: Ross, Aftin <Aftin.Ross@fda.hhs.gov>; Gillespie, Taylor <Gillespie.Taylor@epa.gov>; Beal, Madeline <Beal.Madeline@epa.gov>; Bremer, Kristen <Bremer.Kristen@epa.gov>; Vasu, Amy <Vasu.Amy@epa.gov>

Cc: Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Beckham, Tammy <Tammy.Beckham@fda.hhs.gov>; Steffen, Scott E <Scott.Steffen@fda.hhs.gov>; Mahajan, Babita <Babita.Mahajan@fda.hhs.gov>

Subject: [EXTERNAL] Re: Additional Insights/Information on First EtO Community Meeting in Sandy Utah Post Announcement

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Aftin. I'm copying others who can provide more information about upcoming meetings.

Mike

Sent from my iPhone

On Aug 12, 2022, at 5:19 PM, Ross, Aftin <Aftin.Ross@fda.hhs.gov> wrote:

Good afternoon Mike. I am following up my voicemails with an email recognizing it is late on a Friday. We just became aware that the first community meeting post webinar will be next week in UT for one of the facilities FDA had indicated it was concerned about. It was our understanding that EPA would be engaged in the dialogue regarding facilities for which there were greater supply chain concerns, however it is our understanding that US EPA is not going to participate in this first meeting (we note the web states the meeting date for this community is in October). We wanted to get a better understanding from you regarding EPA's participation in and engagement in setting up this community meeting. We are concerned that the first meeting for a critical facility would lack a federal presence to aid in answering community questions.

Please feel free to give me a call at the cell below. We would like to schedule time on Monday to chat. Would you have time at 10:30 or 11am? If not, when would you have availability to speak?

Best,

Aftin

Aftin Ross, Ph.D.
Senior Special Advisor for Emerging Initiatives
Office of Strategic Partnerships and Technology Innovation (OST)
Center for Devices and Radiological Health
U.S. Food and Drug Administration

WO 66, Room 5558
10903 New Hampshire Ave, Silver Spring, MD 20993
Office: 301-798-5679; Cell: **FDA Ex. 6 PP**
aftin.ross@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received:
<https://www.research.net/s/cdrhcustomerservice?ID=7011&S=E>

